Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.4 (market cap $59.39B), while USA Rare Earth Inc. Class A Common Stock trades at $10.13 (market cap $3.87B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 15.3× USA Rare Earth Inc. Class A Common Stock's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.24% dividend while USA Rare Earth Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 6 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| TAK | USAR | |
|---|---|---|
Market Cap | $59.39B | $3.87B |
Volume | 4,676,421 | 20,993,390 |
Sector | Health | Basic Materials |
52-Week High | $19.05 | $33.68 |
52-Week Low | $13.23 | $10.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $87.25B | $2.35B |
Dividend Yield | 3.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.
Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
